Analyst Joanne Wuensch of Citi maintained a Buy rating on Irhythm Technologies, retaining the price target of $242.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joanne Wuensch’s rating is based on several key considerations regarding Irhythm Technologies. One of the primary factors is the potential impact of proposed Local Coverage Determinations (LCDs) on the company’s revenue. Although these proposals introduce some uncertainty, they are specifically aimed at the Mobile Cardiac Telemetry (MCT) category, and there is an existing National Coverage Determination (NCD) that provides some protection against conflicting LCDs. This regulatory backdrop is crucial in assessing the risk landscape for Irhythm Technologies.
Furthermore, the company’s Zio AT sales, which contribute significantly to its projected revenue, are expected to remain robust despite the proposed changes. With Medicare accounting for a substantial portion of these sales, the existing NCD offers a level of security. Additionally, the anticipated share price return of 41.7% underscores the potential for significant upside, reinforcing the Buy rating. These factors collectively suggest a favorable outlook for Irhythm Technologies, justifying the positive recommendation.
In another report released on November 3, BTIG also reiterated a Buy rating on the stock with a $215.00 price target.